The researchers pooled data from six genome-wide association studies, covering 4,710 people with AML and 12,938 controls. That matters because AML is not a common cancer, and studying inherited risk in a rare disease is a bit like trying to learn traffic patterns from three cars and a bicycle....
Most cancer stories about RNA splicing focus on the protein-coding parts of a message. Fair enough. That is where the protein recipe lives, and recipes feel important when cells are making terrible life choices. But this new Blood paper goes after the parts scientists used to treat a bit like the...
This Blood report zooms in on a 78-year-old man with NPM1-mutated acute myeloid leukemia (AML) plus FLT3-ITD, a combo hematologists know can get messy fast. The weird part was not just that his leukemia came back. It came back looking like it could not decide whether it wanted to be granulocytic or...
Here lies the old pancreatic cancer strategy: throw DNA-damaging chemotherapy at the tumor, cross your fingers, and act surprised when the tumor comes back wearing sunglasses and a fake mustache. It had a long run. Not a great run, but a long one.
Skepticism is fair here - when a paper claims it turned neutrophils into cancer-fighting CAR cells inside the body, your first reaction should be something like, "Sure, and my Wi-Fi only fails when I need it most." But this one is interesting for a real reason: it takes one of the immune system's...
Cancer drugs fail partly because tumor cells are annoyingly good at cleaning up their own mess. A 2026 paper argues that in BRCA1-deficient tumors, one of the cleanup crews is a protein called RPA, and if you knock it out while using a PARP inhibitor, the whole operation can go from "coping" to...
What if one pill could push second-line pancreatic cancer survival past a year? A few years ago that would have sounded like the kind of sentence oncology people say right before someone in the back coughs politely. But as of April 13, 2026, early clinical results around daraxonrasib suggest that...
NCI is the federal government’s main cancer research engine, supporting more than 5,000 grantees, 72 NCI-designated cancer centers, and clinical trials at roughly 2,500 sites across the U.S. (NIH NCI Almanac). NIH overall sends about 82% of its budget to extramural research, meaning the money...
That sounds rude until you remember what early ovarian cancer is asking surgeons to do: remove a dangerous mass without popping it like the world's least forgiving water balloon. The new JAMA Oncology paper by Matsuo and colleagues zeroes in on that exact problem, asking how minimally invasive...
Testicular cancer is one of oncology's big success stories, which is lovely, but also slightly dangerous. When a disease gets labeled "highly curable," people can start acting like the details do not matter. They do. A lot.
Science once blamed combustion on phlogiston, a made-up substance that sounded convincing right up until reality showed up with a folding chair. GlycoRNA has that same "surely not" flavor, except this time the absurd-sounding idea is real: some RNAs can be sugar-coated and displayed on the outside...
Ryan Wexler’s The Liver We Share is not a splashy trial with Kaplan-Meier curves doing gymnastics. It is something rarer in medicine - a story about what happens when the clean lines between student, doctor, caregiver, and spouse get absolutely wrecked by real life. In this case, the wrecking ball...
Cells can enter senescence, which is biology’s version of “you are done dividing, please stop touching the machinery.” That can be helpful. It keeps damaged cells from turning into tumors. But senescent cells also have a bad habit of hanging around like ex-employees who still have the office Slack...
Small cell lung cancer, or SCLC, is one of the most aggressive lung cancers around. It grows fast, spreads early, and has a well-earned reputation for being a nightmare opponent [2,6]. Immunotherapy has helped some patients, but the gains in SCLC have been more "useful but modest" than "cue the...
ALK-positive lung cancer is one of those weirdly specific corners of cancer biology that sounds obscure until you realize how much it changes treatment. In a small slice of lung cancers, the ALK gene gets fused to another gene, creating a permanently jammed-on growth signal. Instead of treating...
When fingerprinting took off in police work, investigators stopped relying quite so much on vibes and started asking for actual evidence. Lung nodule diagnosis could use a little of that energy. A spot shows up on a scan, everyone squints at it, and the big question lands with all the grace of a...
Take one extremely stubborn lymphoma, add several prior treatments that already failed, fold in a patient’s own T cells after some high-tech genetic meddling, and then pray the whole thing does not boil over into cytokine chaos. That is more or less the recipe behind CAR-T therapy for relapsed or...
For years, stomach bacteria were the backup dancers of cancer biology. Colon microbes got the spotlight, gut health got the merch, and the stomach mostly got typecast as "that place with acid." Now this new Gut review argues that the gastric microbiota may be doing a lot more than loitering near...
Here is the core puzzle piece. The authors found that MMRN1 is highly expressed in leukemia stem cells and can switch on EGFR, a signaling receptor better known from solid tumors than blood cancers. Once that pathway lights up, it helps leukemia cells accumulate sialylglycans - sugar structures...
Hepatocellular carcinoma, or HCC, is the main form of primary liver cancer. It is common, deadly, and often found late, which is a lousy combo for everyone involved (Zheng et al., 2025); (Seyhan et al., 2025). One reason HCC is so hard to treat is that liver tumors do not just grow fast. They also...